Macular Degeneration Treatment Market to Surpass US$ 21.1 Bn by 2031: TMR Study – QNT Press Release

  • Massive need for effective treatments for wet age-related macular degeneration presents vast value-grab opportunity for firms in macular degeneration treatment market; growing adoption of anti-VEGF medications for age-related macular degeneration (AMD) propelling revenue generation
  • Europe market to expand at promising pace, spurred by new product launches; enormous demand for treatments at hospitals, especially in elderly

WILMINGTON, Del., Sept. 21, 2022 /PRNewswire/ — Rise in demand for treatments for wet age-related macular degeneration has propelled substantial revenue streams in the market over the years. The segment was the largest revenue generator in macular degeneration treatment market in 2021, and is projected to expand rapidly during the forecast period. The growing burden of retinal disorders has spurred the demand for products in the macular degeneration treatment market. The size of the overall market is estimated to exceed US$ 21.1 Bn by 2031.

Get Exclusive PDF Sample Copy of Macular Degeneration Treatment Market Report –

Recent developments in macular degeneration treatment market underscores that key players are leaning on developing longer-acting anti-VEGF to capture significant revenue shares. High burden of age-related macular degeneration (AMD), pivoting on rapidly aging populations in industrialized nations, underpins enormous revenue potential.

Growing awareness about the effectiveness of intravitreal injections (IVT) for wet AMD has steered revenue generation in macular degeneration treatment market. Many leading players in the macular degeneration treatment market are actively involved in increasing the safety and efficacy of therapies based on anti-vascular endothelial growth factors. R&D on vascular endothelial growth factor (VEGF) will thus create lucrative future market demand for macular degeneration treatment.

Ask for References –

Key Findings of Macular Degeneration Treatment Market Study

  • Abundant Demand for Therapies for Managing Wet Age-Related Macular Degeneration: Massive demand for therapies for wet (exudative or neovascular) age-related macular degeneration is boosting the market growth. Wet AMD is a major cause of visual impairments in elderly, and thus presents a vast avenue. Increase in number of FDA approval of injections has reinforced the growth prospects of macular degeneration treatment market. Wet AMD presents the fastest growing market for macular degeneration treatment. Meanwhile, the study authors found that the adoption of treatments for age-related macular degeneration (AMD) underpins enormous revenue streams. Players are launching novel drugs to gain competitive edge over others.

Full story available on

Source link

Recommended For You

About the Author: News Center